BioIVT – formerly BioreclamationIVT – provides research models and services for drug discovery and development.
“This acquisition will help expand our ability to offer fresh blood products to our clients in the Northeast Corridor. For those researchers conducting immunology studies, using primary cells derived from fresh material is critical for particular cell-based assays,” said Courtney Noah, PhD, BioIVT vice president of marketing.
According to the company, BioIVT will now be able to provide a range of blood-derived cells and cellular products, from leukopak-derived peripheral blood mononuclear cells (PBMCs) to CD34 stem cells.
“With the expanded donor center capabilities, our sourcing teams will be able to work with the BSC collection sites to more rapidly fill requests which come with specific donor demographic requirements,” she told us.
Following the acquisition, BioIVT will retain BSC’s headquarters in Colmar, PA, as well as its two FDA-registered donor centers in Allentown, PA and Reading, PA. The company also will retain all of BSC's employees.
BSC will be integrated into BioIVT’s Biologicals Business Unit, which provides normal human biospecimens to researchers.
The acquisition – financial details of which were not disclosed – comes on the heels of several purchases, including that of Clinical Trials Laboratory Services, a UK-based donor center, last month.
Also in October, the company announced that it will be standardizing its site processes following the string of acquisitions.
